白蛋白输注在肝肾综合征-急性肾损伤诊疗中的研究进展

摘要/Abstract

摘要： 急性肾损伤(AKI)是肝硬化患者常见且严重的合并症,显著增加患者住院时间与病死率。白蛋白输注是肝硬化相关AKI,特别是肝肾综合征-AKI(HRS-AKI)的重要治疗手段。近期,急性疾病质量倡议(ADQI)与国际腹水俱乐部(ICA)联合制定的多学科共识,建议液体复苏的一线治疗优先使用晶体而非白蛋白,且白蛋白输注的时间应限制在24 h内,与欧洲肝脏学会(EASL)指南建议不同。有研究发现EASL的AKI诊疗流程不仅能实现良好的治疗反应率,且不会显著延迟特利加压素治疗的启动时间;同时相当一部分患者的治疗反应出现在24至48 h之间,因此在获得更多证据之前,建议沿用既往HRS-AKI诊断标准,并按照EASL的诊疗流程,白蛋白输注持续至48 h。

宦红娣, 陆春来. 白蛋白输注在肝肾综合征-急性肾损伤诊疗中的研究进展[J]. 肝脏, 2025, 30(11): 1460-1462.

/ 推荐

参考文献

[1] Jones J, Hunter D. Consensus methods for medical and health services research[J]. BMJ,1995,311(7001):376-80.
[2] Nadim M K, Kellum J A, Forni L,et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting[J].J Hepatol,2024,81(1):163-183.
[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460.
[4] Maiwall R, Singh S P, Angeli P,et al. APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure[J]. Hepatol Int, 2024,18(3):833-869.
[5] Ma A T, Solé C, Juanola A,et al. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis[J]. J Hepatol.2024,81(3):441-450.
[6] Ma A T, Juanola A, Solé C, et al. Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin[J].J Hepatol,2025,82(2):e98-e99.
[7] Schleicher E M, Karbannek H, Weinmann-Menke J,et al. Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury[J]. J Hepatol,2025,83(3):682-691.
[8] Angeli P, Labenz C, Piano S, et al. Albumin infusion in hepatorenal syndrome-acute kidney injury: new evidence challenges recent consensus[J].J Hepatol,2025,83(3):800-802.
[9] Gines A, Fernandez-Esparrach G, Monescillo A, et al.Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis[J].Gastroenterology,1996,111(4):1002-1110.
[10] Luca A, García-Pagán JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis[J]. Hepatology,1995,22(3):753-8.
[11] Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J].Gastroenterology.2019,157(1):149-162.
[12] Casulleras M, Flores-Costa R, Duran-Güell M,et al.Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis[J]. Sci Transl Med,2020,12(566):eaax5135.
[13] Angeli P, Gines P, Wong F, et al.Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Gut,2015,64(4):531-537.
[14] Biggins S W, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2021,74(2):1014-1048.
[15] Nadim M K, Kellum J A, Durand F. Reply to: "Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin"[J]. J Hepatol,2025,82(2):e100-e101.
[16] Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. N Engl J Med,1999,341(6):403-409.
[17] Allegretti A S, Patidar K R, Ma A T, et al. From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury[J]. Hepatology,2025, 81(6):1878-1897.
[18] China L, Freemantle N, Forrest E,et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis[J]. N Engl J Med,2021,384(9):808-817.
[19] Ortega R, Ginès P, Uriz J,et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study[J]. Hepatology,2002,36(4 Pt 1):941-948.
[20] Jindal A, Singh H, Kumar G, et al. Early versus standard initiation of terlipressin for acute kidney injury in ACLF: a randomized controlled trial (eTerli Study). Dig Dis Sci[J]. 2024,69(6):2204-2214.